|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2763701B1
(en)
|
2011-10-03 |
2018-12-19 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
JP2015501844A
(ja)
|
2011-12-16 |
2015-01-19 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
|
|
WO2013143555A1
(en)
*
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
CN103254260B
(zh)
*
|
2013-02-07 |
2015-11-11 |
江西科技师范大学 |
由核苷氢亚磷酸单酯合成对称双核苷二磷酸二钠盐的方法
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
EP2971161B1
(en)
|
2013-03-15 |
2018-12-26 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP2971033B8
(en)
*
|
2013-03-15 |
2019-07-10 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
EP2983804A4
(en)
|
2013-03-15 |
2017-03-01 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US10077439B2
(en)
|
2013-03-15 |
2018-09-18 |
Modernatx, Inc. |
Removal of DNA fragments in mRNA production process
|
|
HUE056760T2
(hu)
|
2013-07-11 |
2022-03-28 |
Modernatx Inc |
A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
EP3540060A1
(en)
|
2013-12-30 |
2019-09-18 |
CureVac AG |
Methods for rna analysis
|
|
AU2014375404C1
(en)
|
2013-12-30 |
2020-11-19 |
CureVac Manufacturing GmbH |
Methods for RNA analysis
|
|
US10837039B2
(en)
|
2014-06-10 |
2020-11-17 |
Curevac Real Estate Gmbh |
Methods and means for enhancing RNA production
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
CA2955238A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
WO2016077125A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
|
JP6909157B2
(ja)
|
2014-12-16 |
2021-07-28 |
ノバルティス アーゲー |
エンドキャップされた核酸分子
|
|
EP4019635A1
(en)
|
2015-03-25 |
2022-06-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
|
EP3173092B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
EP3294896A1
(en)
|
2015-05-11 |
2018-03-21 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
CA2985615A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
|
PL4108769T3
(pl)
|
2015-05-29 |
2024-02-05 |
CureVac Manufacturing GmbH |
Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
|
|
KR102796744B1
(ko)
|
2015-06-09 |
2025-04-15 |
에디타스 메디신, 인코포레이티드 |
이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
|
|
WO2017001058A1
(en)
|
2015-07-01 |
2017-01-05 |
Curevac Ag |
Method for analysis of an rna molecule
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
WO2017049286A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
|
SI3350333T1
(sl)
|
2015-09-17 |
2022-04-29 |
ModernaTX,Inc. |
Polinukleotidi, ki zajemajo stabilizacijsko repno regijo
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
*
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
WO2017066781A1
(en)
*
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
|
EP3365447A1
(en)
|
2015-10-21 |
2018-08-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hepatitis b virus
|
|
JP7408284B2
(ja)
|
2015-10-30 |
2024-01-05 |
エディタス・メディシン、インコーポレイテッド |
単純ヘルペスウイルスを治療するためのcrispr/cas関連方法及び組成物
|
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
|
US11248223B2
(en)
|
2015-12-23 |
2022-02-15 |
Curevac Ag |
Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
WO2017112943A1
(en)
|
2015-12-23 |
2017-06-29 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
PL415967A1
(pl)
*
|
2016-01-29 |
2017-07-31 |
Univ Warszawski |
5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
|
|
EP4289965A3
(en)
|
2016-02-12 |
2024-02-21 |
CureVac SE |
Method for analyzing rna
|
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
US20190167811A1
(en)
|
2016-04-13 |
2019-06-06 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
WO2017191264A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Nucleic acid molecules and uses thereof
|
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
|
WO2017201325A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Combinations of mrnas encoding immune modulating polypeptides and uses thereof
|
|
EP3896164A1
(en)
|
2016-05-18 |
2021-10-20 |
ModernaTX, Inc. |
Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
|
|
WO2017201349A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
DK3458083T5
(da)
|
2016-05-18 |
2024-10-21 |
Modernatx Inc |
Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
|
|
US11001861B2
(en)
|
2016-05-18 |
2021-05-11 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
AU2017266948B2
(en)
|
2016-05-18 |
2024-07-04 |
Fundacion Para La Investigacion Medica Aplicada |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US12385034B2
(en)
|
2016-06-24 |
2025-08-12 |
Modernatx, Inc. |
Methods and apparatus for filtration
|
|
CA3025812A1
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
|
MX2019004913A
(es)
|
2016-10-26 |
2019-09-16 |
Curevac Ag |
Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
CN119351474A
(zh)
|
2017-02-22 |
2025-01-24 |
克里斯珀医疗股份公司 |
用于基因编辑的组合物和方法
|
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
CA3062595A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
|
ES2952779T3
(es)
|
2017-05-18 |
2023-11-06 |
Modernatx Inc |
ARN mensajero modificado que comprende elementos de ARN funcionales
|
|
US11421011B2
(en)
|
2017-05-18 |
2022-08-23 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
|
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
US10034951B1
(en)
|
2017-06-21 |
2018-07-31 |
New England Biolabs, Inc. |
Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
|
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
|
WO2019036638A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR PREPARING MODIFIED RNA
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
US20200283497A1
(en)
|
2017-09-13 |
2020-09-10 |
Biontech Cell & Gene Therapies Gmbh |
Rna replicon for expressing at cell receptor or an artificial t cell receptor
|
|
WO2019053012A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Rna Pharmaceuticals Gmbh |
RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS
|
|
US20200362313A1
(en)
|
2017-09-13 |
2020-11-19 |
Biontech Rna Pharmaceuticals Gmbh |
Method of enhancing rna expression in a cell
|
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
|
EP3714048B1
(en)
|
2017-11-22 |
2025-04-09 |
ModernaTX, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
|
JP7424976B2
(ja)
|
2017-11-22 |
2024-01-30 |
モダーナティエックス・インコーポレイテッド |
プロピオン酸血症の治療用のプロピオニルCoAカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
|
|
WO2019104160A2
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
CN111511928A
(zh)
|
2017-12-21 |
2020-08-07 |
库瑞瓦格股份公司 |
偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
|
|
EP3735270A1
(en)
|
2018-01-05 |
2020-11-11 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
EP3773745A1
(en)
|
2018-04-11 |
2021-02-17 |
ModernaTX, Inc. |
Messenger rna comprising functional rna elements
|
|
DE202019006199U1
(de)
|
2018-04-17 |
2026-01-12 |
CureVac SE |
Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
|
|
FR3081169B1
(fr)
*
|
2018-05-15 |
2020-06-19 |
Messenger Biopharma |
Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
|
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
WO2020047201A1
(en)
|
2018-09-02 |
2020-03-05 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
|
WO2020056155A2
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
|
EP3849595B1
(en)
|
2018-09-13 |
2025-11-19 |
ModernaTX, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
|
|
US20220401584A1
(en)
|
2018-09-14 |
2022-12-22 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
EP3856233A1
(en)
|
2018-09-27 |
2021-08-04 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
|
WO2020072914A1
(en)
|
2018-10-04 |
2020-04-09 |
New England Biolabs, Inc. |
Methods and compositions for increasing capping efficiency of transcribed rna
|
|
US11072808B2
(en)
*
|
2018-10-04 |
2021-07-27 |
New England Biolabs, Inc. |
Methods and compositions for increasing capping efficiency of transcribed RNA
|
|
CN113453707A
(zh)
|
2018-12-21 |
2021-09-28 |
库瑞瓦格股份公司 |
用于疟疾疫苗的rna
|
|
US12492425B2
(en)
|
2018-12-21 |
2025-12-09 |
CureVac SE |
Methods for RNA analysis
|
|
KR20210133218A
(ko)
|
2019-01-31 |
2021-11-05 |
모더나티엑스, 인크. |
볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
|
|
MX2021009245A
(es)
|
2019-01-31 |
2021-11-12 |
Modernatx Inc |
Metodos de preparacion de nanoparticulas lipidicas.
|
|
EP4491229A3
(en)
|
2019-02-08 |
2025-05-14 |
CureVac SE |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
CN114375190A
(zh)
|
2019-05-08 |
2022-04-19 |
阿斯利康(瑞典)有限公司 |
用于皮肤和伤口的组合物及其使用方法
|
|
US20220370354A1
(en)
|
2019-05-08 |
2022-11-24 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
WO2020263883A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
|
US20220387628A1
(en)
|
2019-06-24 |
2022-12-08 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
|
WO2021026358A1
(en)
|
2019-08-07 |
2021-02-11 |
Moderna TX, Inc. |
Compositions and methods for enhanced delivery of agents
|
|
JP2022544412A
(ja)
|
2019-08-14 |
2022-10-18 |
キュアバック アーゲー |
免疫賦活特性が減少したrna組み合わせおよび組成物
|
|
AU2020366209A1
(en)
|
2019-10-15 |
2022-05-19 |
Board Of Regents Of The University Of Nebraska |
mRNA encoding granulocyte-macrophage colony stimulating factor for treating Parkinson's disease
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
EP3886897A1
(en)
|
2020-02-04 |
2021-10-06 |
CureVac AG |
Coronavirus vaccine
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
PL432884A1
(pl)
*
|
2020-02-12 |
2021-08-16 |
Uniwersytet Warszawski |
Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
|
|
KR102924173B1
(ko)
|
2020-04-09 |
2026-02-06 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 나노입자 조성물
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
CN113521269A
(zh)
|
2020-04-22 |
2021-10-22 |
生物技术Rna制药有限公司 |
冠状病毒疫苗
|
|
JP2023526059A
(ja)
|
2020-05-14 |
2023-06-20 |
モダーナティエックス・インコーポレイテッド |
mRNA治療薬及びエフェクター分子を含むLNP組成物
|
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|
|
CA3184474A1
(en)
|
2020-06-01 |
2021-12-09 |
Modernatx, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
|
EP4157217A1
(en)
|
2020-06-01 |
2023-04-05 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
|
EP4162034A1
(en)
|
2020-06-04 |
2023-04-12 |
BioNTech SE |
Rna replicon for versatile and efficient gene expression
|
|
IL299196A
(en)
|
2020-06-23 |
2023-02-01 |
Modernatx Inc |
LNP preparations that include mRNA treatments with extended lifespan
|
|
AU2021301922A1
(en)
|
2020-06-30 |
2023-02-02 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
CN116710079A
(zh)
|
2020-07-24 |
2023-09-05 |
斯特兰德生物科技公司 |
包含经修饰的核苷酸的脂质纳米颗粒
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
WO2022037652A1
(en)
|
2020-08-20 |
2022-02-24 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
CA3170743A1
(en)
|
2020-08-31 |
2022-03-03 |
Susanne RAUCH |
Multivalent nucleic acid based coronavirus vaccines
|
|
EP4208549A4
(en)
|
2020-09-04 |
2025-04-16 |
Verve Therapeutics, Inc. |
Compositions and methods for capping RNAs
|
|
KR20230118715A
(ko)
|
2020-10-14 |
2023-08-11 |
조지 메이슨 리서치 파운데이션 인코포레이티드 |
이온화 가능 지질 및 이의 제조 및 사용 방법
|
|
WO2022104131A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
JP2023552681A
(ja)
|
2020-11-16 |
2023-12-19 |
ビオンテック・ソシエタス・エウロパエア |
製剤安定化の向上および凍結乾燥プロセスの改善
|
|
JP2023552468A
(ja)
|
2020-12-09 |
2023-12-15 |
ビオンテック・ソシエタス・エウロパエア |
Rnaの製造
|
|
US20240299309A1
(en)
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
AU2022205679A1
(en)
|
2021-01-08 |
2023-07-06 |
Strand Therapeutics Inc. |
Expression constructs and uses thereof
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022152141A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Polymer conjugated lipid compounds and lipid nanoparticle compositions
|
|
EP4087938A2
(en)
|
2021-01-27 |
2022-11-16 |
CureVac AG |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
JP2024506908A
(ja)
|
2021-02-12 |
2024-02-15 |
モデルナティエックス インコーポレイテッド |
インビボ療法のためのペイロードを含むlnp組成物
|
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
|
US20240226025A1
(en)
|
2021-03-24 |
2024-07-11 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
WO2022204370A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
|
MX2023011400A
(es)
|
2021-03-26 |
2023-10-09 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogenicas.
|
|
EP4314284A1
(en)
|
2021-03-31 |
2024-02-07 |
Modernatx, Inc. |
Purification and recycling of mrna nucleotide caps
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4314332A2
(en)
|
2021-04-01 |
2024-02-07 |
ModernaTX, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
WO2022234417A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Immunogenic composition against influenza
|
|
WO2022234405A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
|
US20240269248A1
(en)
|
2021-05-19 |
2024-08-15 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
WO2022247755A1
(en)
|
2021-05-24 |
2022-12-01 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
US20240384277A1
(en)
|
2021-06-15 |
2024-11-21 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
|
US20240376445A1
(en)
|
2021-06-22 |
2024-11-14 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
WO2023287751A1
(en)
|
2021-07-12 |
2023-01-19 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
|
US20250090684A1
(en)
|
2021-07-27 |
2025-03-20 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
|
|
WO2023007019A1
(en)
|
2021-07-30 |
2023-02-02 |
CureVac SE |
Cap analogs having an acyclic linker to the guanine derivative nucleobase
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
EP4392140A1
(en)
|
2021-08-24 |
2024-07-03 |
BioNTech SE |
In vitro transcription technologies
|
|
CN117940158A
(zh)
|
2021-09-03 |
2024-04-26 |
库瑞瓦格欧洲公司 |
用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
|
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
|
AU2022358824A1
(en)
|
2021-10-08 |
2024-04-11 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
EP4412646A1
(en)
|
2021-10-08 |
2024-08-14 |
Pfizer Inc. |
Immunogenic lnp compositions and methods thereof
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
AU2022369342A1
(en)
|
2021-10-18 |
2024-03-14 |
BioNTech SE |
Modified replicable rna and related compositions and their use
|
|
WO2023066874A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
|
|
WO2023077170A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Polynucleotides encoding integrin beta-6 and methods of use thereof
|
|
US20240200078A1
(en)
|
2021-11-18 |
2024-06-20 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
|
US12186387B2
(en)
|
2021-11-29 |
2025-01-07 |
BioNTech SE |
Coronavirus vaccine
|
|
KR20240116841A
(ko)
|
2021-12-17 |
2024-07-30 |
화이자 인코포레이티드 |
폴리뉴클레오티드 조성물 및 그의 용도
|
|
CA3241492A1
(en)
|
2021-12-23 |
2023-06-29 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compound and lipid nanoparticle composition
|
|
WO2023138786A1
(en)
|
2022-01-21 |
2023-07-27 |
BioNTech SE |
Analysis of rna molecules using catalytic nucleic acids
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
US20250213664A1
(en)
|
2022-02-18 |
2025-07-03 |
Modernatx, Inc. |
Mrnas encoding checkpoint cancer vaccines and uses thereof
|
|
US12037616B2
(en)
|
2022-03-01 |
2024-07-16 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions
|
|
TW202403046A
(zh)
|
2022-03-21 |
2024-01-16 |
瑞士商Crispr治療公司 |
用於治療脂蛋白相關的疾病之方法及組成物
|
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
|
WO2023201294A1
(en)
|
2022-04-14 |
2023-10-19 |
Modernatx, Inc. |
Rna polymerase variants
|
|
IL316186A
(en)
|
2022-04-26 |
2024-12-01 |
Strand Therapeutics Inc |
Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
|
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
CA3248209A1
(en)
|
2022-05-25 |
2023-11-30 |
CureVac SE |
Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
|
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
|
MA71619A
(fr)
|
2022-07-26 |
2025-05-30 |
Modernatx, Inc. |
Polynucléotides modifiés pour la régulation temporelle de l'expression
|
|
CN119866224A
(zh)
|
2022-07-28 |
2025-04-22 |
加拿大干细胞技术公司 |
编码连接抗原的多核苷酸以及其用途
|
|
JP2025527583A
(ja)
|
2022-08-18 |
2025-08-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子の組成物
|
|
CA3267295A1
(en)
|
2022-09-15 |
2024-03-21 |
TRON – TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH-Aysegul YILDIZ |
SYSTEMS AND COMPOSITIONS CONTAINING TRANS-AMPLIFYING RNA VECTORS WITH MIARN
|
|
US20250387764A1
(en)
|
2022-09-15 |
2025-12-25 |
Pfizer Inc. |
Coaxial flow device for nanoparticle preparation and manufacturing equipment including such device
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
|
WO2024119117A1
(en)
*
|
2022-12-02 |
2024-06-06 |
Prime Medicine, Inc. |
Modified 5' cap for mrna and methods of use thereof
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
EP4637717A1
(en)
|
2022-12-23 |
2025-10-29 |
Pfizer Inc. |
Lipid particle compositions and methods of use thereof
|
|
EP4648793A1
(en)
|
2023-01-11 |
2025-11-19 |
ModernaTX, Inc. |
Personalized cancer vaccines
|
|
WO2024154061A1
(en)
|
2023-01-18 |
2024-07-25 |
Pfizer Inc. |
Compositions and methods for stabilizing rna
|
|
EP4658664A1
(en)
|
2023-01-31 |
2025-12-10 |
CureVac SE |
Cap analogs with 5'-terminal acyclic guanosine derivative
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
WO2024165146A1
(en)
|
2023-02-07 |
2024-08-15 |
Biontech Cell & Gene Therapies Gmbh |
Immune effector cells stably and transiently expressing nucleic acids
|
|
EP4665390A1
(en)
|
2023-02-13 |
2025-12-24 |
Pfizer Inc. |
Immunogenic composition against influenza
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024178305A1
(en)
|
2023-02-24 |
2024-08-29 |
Modernatx, Inc. |
Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
|
|
WO2024182301A2
(en)
|
2023-02-27 |
2024-09-06 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia
|
|
JP2026509258A
(ja)
|
2023-03-08 |
2026-03-17 |
キュアバック エスイー |
核酸送達のための新規な脂質ナノ粒子製剤
|
|
WO2024197033A1
(en)
|
2023-03-21 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of heart failure
|
|
WO2024206126A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Cd16-binding antibodies and uses thereof
|
|
WO2024206329A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
|
|
JP2026512425A
(ja)
|
2023-03-30 |
2026-04-16 |
オーエスイー・イミュノセラピューティクス |
免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
|
|
EP4687990A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
JP2026513742A
(ja)
|
2023-04-12 |
2026-05-01 |
ストランド セラピューティクス インコーポレイテッド |
合成回路及びその使用
|
|
WO2024216217A1
(en)
|
2023-04-14 |
2024-10-17 |
BioNTech SE |
Hiv vaccine
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
AU2024265267A1
(en)
|
2023-05-03 |
2025-11-20 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
EP4464713A1
(en)
|
2023-05-18 |
2024-11-20 |
Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii |
Circular rna analogs, preparation and application thereof
|
|
KR20260020489A
(ko)
|
2023-06-14 |
2026-02-11 |
화이자 인코포레이티드 |
Rna를 안정화시키는 방법
|
|
US20250027087A1
(en)
|
2023-07-21 |
2025-01-23 |
Crispr Therapeutics Ag |
Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
|
|
WO2025024559A1
(en)
|
2023-07-24 |
2025-01-30 |
Strand Therapeutics Inc. |
Rna-based synthetic circuit for producing engineered immune cells for an extracorporeal cell therapy
|
|
KR20260046366A
(ko)
|
2023-07-25 |
2026-04-07 |
스트랜드 세러퓨틱스 인코포레이티드 |
마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도
|
|
CN121941694A
(zh)
|
2023-08-03 |
2026-04-28 |
垂林克生物技术有限公司 |
帽类似物及其使用方法
|
|
WO2025042806A2
(en)
|
2023-08-21 |
2025-02-27 |
Modernatx, Inc. |
C-met binding antibodies, nucleic acids encoding same, and methods of use
|
|
WO2025051381A1
(en)
|
2023-09-08 |
2025-03-13 |
BioNTech SE |
Methods and compositions for localized expression of administered rna
|
|
IL326633A
(en)
|
2023-09-13 |
2026-04-01 |
Pfizer |
Immunogenic preparations against influenza
|
|
WO2025059290A1
(en)
|
2023-09-14 |
2025-03-20 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
WO2025072482A1
(en)
|
2023-09-27 |
2025-04-03 |
Modernatx, Inc. |
Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
|
|
WO2025074292A2
(en)
|
2023-10-06 |
2025-04-10 |
Pfizer Inc. |
Immunogenic compositions
|
|
US20250332245A1
(en)
|
2023-11-15 |
2025-10-30 |
Pfizer Inc. |
Immunogenic compositions against influenza
|
|
WO2025111297A1
(en)
|
2023-11-21 |
2025-05-30 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
US20250269059A1
(en)
|
2024-02-27 |
2025-08-28 |
Crispr Therapeutics Ag |
Rt editing compositions and methods
|
|
WO2025184429A1
(en)
|
2024-02-28 |
2025-09-04 |
Modernatx, Inc. |
Bromodomain and extra-terminal domain (bet) epigenetic reader decoy
|
|
WO2025186726A1
(en)
|
2024-03-05 |
2025-09-12 |
Crispr Therapeutics Ag |
Modulating expression of agt (angiotensinogen) gene
|
|
WO2025186725A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Improved lnp formulations and uses thereof
|
|
TW202602467A
(zh)
|
2024-03-11 |
2026-01-16 |
美商輝瑞股份有限公司 |
包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
|
|
WO2025202834A1
(en)
|
2024-03-26 |
2025-10-02 |
Pfizer Inc. |
Polynucleotide compositions and uses thereof
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025212851A2
(en)
|
2024-04-03 |
2025-10-09 |
Orbital Therapeutics, Inc. |
mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES
|
|
WO2025217591A1
(en)
|
2024-04-12 |
2025-10-16 |
Strand Therapeutics Inc. |
Human-derived synthetic regulators and uses thereof
|
|
WO2025238563A1
(en)
|
2024-05-17 |
2025-11-20 |
Pfizer Inc. |
Coaxial mixing device for nanoparticle preparation and manufacturing equipment including such mixing device
|
|
WO2025255199A1
(en)
|
2024-06-05 |
2025-12-11 |
Modernatx, Inc. |
Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
|
|
WO2026025031A1
(en)
|
2024-07-26 |
2026-01-29 |
Modernatx, Inc. |
Mrna encoding mageb2 tcer molecule
|
|
WO2026044055A1
(en)
|
2024-08-23 |
2026-02-26 |
Modernatx, Inc. |
Muc16 binding molecules, nucleic acids encoding same, and methods of use
|
|
WO2026075820A1
(en)
|
2024-10-03 |
2026-04-09 |
Modernatx, Inc. |
4-1bb binding molecules, nucleic acids encoding same, and methods of use
|
|
WO2026085234A1
(en)
|
2024-10-18 |
2026-04-23 |
Modernatx, Inc. |
3' untranslated region sequences for extending messenger ribonucleic acids half-life
|
|
WO2026088119A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Lipidated tlr7/8 modulators as adjuvants and uses thereof
|
|
WO2026096575A1
(en)
|
2024-10-29 |
2026-05-07 |
Modernatx, Inc. |
Mrna encoding concatemeric prame epitope polypeptide
|